Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||1.90%||8.03||0.7%||$561.33m|
|GILD||Gilead Sciences, Inc.||0.72%||65.77||1.0%||$463.29m|
|REGN||Regeneron Pharmaceuticals, Inc.||2.80%||494.64||2.7%||$449.68m|
|VRTX||Vertex Pharmaceuticals, Inc.||1.83%||221.10||1.9%||$383.88m|
|ALXN||Alexion Pharmaceuticals, Inc.||1.45%||157.54||2.0%||$298.86m|
|EXAS||EXACT Sciences Corp.||2.66%||130.52||18.4%||$192.20m|
|NBIX||Neurocrine Biosciences, Inc.||-0.05%||95.00||4.9%||$177.73m|
|CRSP||CRISPR Therapeutics AG||0.60%||123.85||0.6%||$174.50m|
CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.